WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial ( ...

Ardelyx (ARDX) shares soared 16% in the last trading session to close at $5.88. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.9% loss over the past four weeks.The stock rallied after the company announced preliminary total U.S. net product sales of $319 million in 2024, backed by growing demand for its two drugs, Ibsrela and Xphozah. Ibsrela sales in the fourth quarter of 2024 are expected to be $54 million, bringing the full ...

Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited) Company reaffirms peak U.S. net IBSRELA sales revenue of greater than $1 Billion Company announces peak U.S. net XPHOZAH sales revenue of $750 million Company finishes 2024 with approximately $250 million in cash, cash equivalents and investments (unaudited) WALTHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical c ...

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] Upcoming Events - Mike Raab, President and CEO of Ardelyx, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 4:30 PM PT in San Francisco [1] - A live webcast of the presentation will be available on the Ardelyx website, with a replay accessible for 30 days post-event [2]

Ardelyx (NASDAQ: ARDX ) lost the lawsuit against Medicare, the one that I was worried about in my earlier article . With that loss, XPHOZAH faces the prospect of much reduced and declining revenue. ARDX has no other major prospectAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For ...

WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30pm EST in New Y ...

I'm an investment analyst with clinical experience in healthcare and an MBA, expanding my focus from biotech to a range of sectors. I've had the privilege of sharing my insights on Seeking Alpha since 2017, emphasizing financial modeling techniques like DCF analysis to identify underlying assumptions in stock valuations. I provide scenario-based forecasts to help readers gauge reasonable outcomes. Influenced by works like Superforecasting and Antifragile, I advocate for disciplined risk management through a ...

Core Viewpoint - Ardelyx, Inc. has faced a legal setback as the U.S. District Court has granted a motion to dismiss a lawsuit that would have protected patient access to its drug XPHOZAH, allowing the Centers for Medicare and Medicaid Services (CMS) to include phosphate lowering therapies in the Medicare End-Stage Renal Disease Prospective Payment System starting January 1, 2025 [1][2][3] Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs, with two commercial products approved in the U.S., including XPHOZAH and IBSRELA [9] Product Information - XPHOZAH (tenapanor) was approved by the FDA in October 2023 to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, particularly for those who do not respond adequately to phosphate binders [4][8] - The drug is taken as a single tablet twice daily and offers a first-in-class mechanism that blocks phosphate absorption [4] Market Context - Hyperphosphatemia, characterized by elevated phosphate levels in the blood, affects the majority of the 550,000 patients in the U.S. with CKD on maintenance dialysis, necessitating effective treatment options [5] - The current treatment guidelines recommend lowering elevated phosphate levels to a normal range of 2.5-4.5 mg/dL [5] Legal and Regulatory Developments - The court's decision allows CMS to implement a bundled payment system that may restrict access to essential medications for dialysis patients, which has raised concerns among patient advocates and the company [2][3] - Ardelyx is exploring all options related to the lawsuit and is committed to protecting patient access to XPHOZAH [3]

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2 ...

Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President & Chief Executive Officer Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial Officer & Chief Operations Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Dennis Ding - Jefferies Roanna Ruiz - Leerink Partners Laura Chico - Wedbush Joseph Thome - TD Cowen Ryan ...